William Jordan is co-chair of the Litigation & Trial Practice Group. He concentrates his practice on business litigation, government and internal corporate investigations, corporate ethics and compliance matters, and antitrust law. Bill is a member of the firm's Government Investigations & Special Matters Team and leads its Health Care Litigation Team. He frequently represents hospitals, pharmaceutical companies, insurers, health care providers, chemical manufacturers, telecommunications and technology providers, and financial services companies in offensive and defensive litigation, corporate compliance matters and government investigations. He also serves as outside ethics and compliance counsel to a number of companies, including multinational chemical and manufacturing companies and health care providers. Bill has represented companies in civil litigation throughout the country in complex matters involving unfair trade practices, antitrust law, health care regulation, civil RICO and the False Claims Act. He also has represented clients in government and congressional investigations involving health care fraud, the NSA’s terrorist surveillance program, computer crime and the Foreign Corrupt Practices Act.
From 2001-2003, Bill served as a senior official in the Department of Justice—from 2001-2003, as Senior Counsel to the Assistant Attorney General for the Civil Division; and in 2003, as Senior Counsel to the Associate Attorney General of the United States.
- Represented nation’s largest publicly-traded hospital chain in civil and criminal investigations throughout the country involving health care fraud matters. Negotiated favorable settlement of many investigations and obtained judicial dismissal of one matter involving allegedly unauthorized medical procedures.
- Represented New Orleans hospitals in criminal investigations and congressional hearings related to their response to Hurricane Katrina, including allegations that patients were euthanized in the immediate aftermath of the storm.
- Represented clients in state Attorneys General, Medicaid Fraud Control Unit, and federal investigations in over 20 states and in every federal circuit.
- Obtained $10.3MM judgment for a private college in civil RICO claim alleging fraud in theft of assets involving timber and real estate interests.
- Defended major telecommunications company in multiple class actions alleging that it had impermissibly revealed confidential customer information to government through the National Security Agency’s Terrorist Surveillance Program.
- Represented individual in Senate Judiciary Committee hearing related to alleged firing of U.S. Attorneys and political hiring at Department of Justice.
- Conducted numerous internal investigations related to alleged government fraud, FCPA issues and antitrust matters.
- Serve as outside global ethics and compliance counsel to world’s second largest chemical company.
One hundred and forty-seven Alston & Bird lawyers have been selected by their peers for inclusion in the 2015 edition of The Best Lawyers In America. The lawyers span the firm’s eight U.S. offices and represent more than 60 different practice areas.
August 19, 2014
Twenty-one Alston & Bird practices have been listed in the 2014 Chambers USA: America’s Leading Lawyers for Business. These include Antitrust; Banking & Finance; Bankruptcy/Restructuring; Construction; Corporate/M&A; Employee Benefits & Executive Compensation; Energy; Environment; ERISA Litigation; Government: Government Relations; Healthcare; Immigration; Intellectual Property; International Trade; Labor & Employment; Litigation: General Commercial, including White-Collar and Securities Litigation; Outsourcing; Privacy & Data Security; Real Estate; REITs; and Tax.
May 23, 2014
In the News
Alston & Bird advised Harden Healthcare Holdings, Inc., in its $410 million tax-free merger with Gentiva Health Services, Inc. (GTIV).
October 13, 2013
In the News
One hundred and forty-four Alston & Bird attorneys have been selected for inclusion in the 2014 edition of The Best Lawyers in America. In addition, 17 Alston & Bird attorneys were named “Lawyer of the Year” by the publication.
August 15, 2013
In the News
Most False Claims Act practitioners have a checklist of potential defenses to evaluate when first learning of a qui tam lawsuit. Is the relator the first to file?
February 4, 2015
Trends features updates on key legal issues in litigation and about Alston & Bird’s litigation practices. In this edition’s lead article, Craig Carpenito, co-leader of the Government & Internal Investigations Group, interviews several litigation partners who have joined Alston & Bird in recent months—Stephanie Clouston in Dallas; Charles Cox, Jim Evans and Mark Johnson, all in Los Angeles; John Roesser in New York; and Ted Kang in Washington, D.C. These six seasoned litigators add breadth and depth to the firm’s litigation practice. Next, Susan Hurd and Cara Peterman of our Securities Litigation Group examine the impact of the recent Supreme Court Amgen decision on the standard for certification of a class action. Bill Jordan and Jason Popp in our Litigation & Trial Practice Group then consider the new Resource Guide to the U.S. Foreign Corrupt Practices Act and how it may help companies conducting business in foreign countries comply with the FCPA. Finally, Matt McGuire and Rich McAvoy, also members of our Litigation & Trial Practice Group, review the Consumer Financial Protection Bureau’s newly issued qualified mortgage and mortgage servicing rules, which take effect in early 2014.
June 3, 2013
In recent years, the pharmaceutical industry has been a frequent target of Foreign Corrupt Practices Act (FCPA) investigations. Since 2009, when Assistant Attorney General Lanny Breuer warned that the Department of Justice (DOJ) would be “intensely focused on rooting out foreign bribery in [the pharmaceutical] industry,” eight of the world’s 10-largest drugmakers have indicated that they may be facing FCPA liability, and many more have received letters of inquiry from DOJ. The government has paid particular attention to potentially improper payments associated with clinical trials conducted abroad. This article discusses recent developments in this arena and how pharmaceutical companies and medical device makers can best protect themselves from FCPA liability.
November 26, 2012
16 January 2012